Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion

Allergy and Asthma Proceedings

Volumn 23, Issue 5, 2002, Pages 325-330

  Schenkel, Eric ^a   Corren, Jonathan ^b   Murray, John J ^c  

^a Valley Clinical Research Center   (United States)

^b Allergy Research Foundation   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DESLORATADINE; DRUG DERIVATIVE; EPHEDRINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HAY FEVER; HOSPITALIZATION; HUMAN; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EPHEDRINE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; NASAL OBSTRUCTION; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; SYMPATHOMIMETICS;

EID: 0036728559     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nacleno RM. Allergic rhinitis. N Engl J Med 325:860-869, 1991.
2. American Academy of Allergy, Asthma, and Immunology. Rhinitis. The Allergy Report, Vol. 2: Diseases of the Atopic Diathesis. Milwaukee. WI American Academy of Allergy. Asthma, and Immunology, 2000 pp 1-30.
3. Juniper EF. and Guyatt GH. Development and testing of a newmeasure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83, 1991.
4. Juniper EF, Guyatt GH, and Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 93:413-423, 1994.
5. Young T, Finn L, and Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 99:S757-S762. 1997.
6. Wilken J. Decrements in cognitive functioning associated with seasonal allergic rhinitis Allergy 55(suppl 63): 193, 2000.
7. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21:7-13, 2000.
8. McNicholas WT, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 126:625-628, 1982.
9. Shturman-Ellstein R, Zeballos RJ, Buckley JM. et al. The beneficial effect of nasal breathing on exercise-induced bronchoconstriction. Am Rev Respir Dis 118:65-73, 1978.
10. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 82:296-305, 1999.
11. Baroody FM, and Naclerio RM. Antiallergic effects of H1 -receptor antagonists. Allergy 55(suppl 64):17-27, 2000
12. Geha RS, and Mettzer EO. Desloratadine: a new, nonsedating oral antihistamine. J Allergy Clin Immunol 107:751-762, 2001
13. Hadley JA. Evaluation and management of allergic rhinitis. Med Clin North Am 83:13-25, 1999.
14. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 96:139-147, 1995.
15. 1-receptor antagonist in patients with seasonal allergic rhinitis. Clin Drag Invest 21:25-32, 2001.
16. Clarinex (desloratadine) Prescribing Information. Schering Corporation, Kenilworth, NJ, 2002.
17. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 56(suppl 65): 14-20, 2001.
18. Howarth PH, Stern MA. Reynolds R. et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochlonde (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 104:927-933, 1999.
19. Pearlman DS, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controiled study. Clin Pediatr 36.209-215, 1997.
20. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochlonde for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 79:443-448, 1997.
21. Casale TB, Andrade C, and Qu R Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 20:193-198, 1999.
22. Nayak AS, and Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56:1077-1080, 2001.
23. Lorber R, Salmun LM, and Danzig MR Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis. New Trends Allergy In press.
24. Nathan R, and Desloratadine Study Group. Desloraiadine relieved nasal congestion in patients with seasonal allergic rhinitis and concurrent asthma. Ann Allergy Asthma Immunol 86:84, 2001.
25. Daly AF. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine and loratadine. Allergy 56(suppl 68):79, 2001.